HRP20200044T1 - Derivati 2-aminopiridina kao antagonisti adenozinskog receptora a2b i ligandi melatoninskih receptora mt3 - Google Patents

Derivati 2-aminopiridina kao antagonisti adenozinskog receptora a2b i ligandi melatoninskih receptora mt3 Download PDF

Info

Publication number
HRP20200044T1
HRP20200044T1 HRP20200044TT HRP20200044T HRP20200044T1 HR P20200044 T1 HRP20200044 T1 HR P20200044T1 HR P20200044T T HRP20200044T T HR P20200044TT HR P20200044 T HRP20200044 T HR P20200044T HR P20200044 T1 HRP20200044 T1 HR P20200044T1
Authority
HR
Croatia
Prior art keywords
pyridin
amine
fluoropyridin
chloro
unbranched
Prior art date
Application number
HRP20200044TT
Other languages
English (en)
Inventor
Julio Cesar Castro-Palomino Laria
Juan Alberto CAMACHO GÓMEZ
Adela MENDOZA LIZALDEZ
Original Assignee
Palobiofarma, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma, S.L. filed Critical Palobiofarma, S.L.
Publication of HRP20200044T1 publication Critical patent/HRP20200044T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (15)

1. Spoj formule (I): , naznačen time što: – R1 predstavlja atom halogena ili atom vodika; – R2 predstavlja šesteročlani heteroarilni prsten koji sadrži ugljik, vodik i jedan ili više atoma dušika, koji može biti supstituiran s jednim ili više supstituenata, koje se bira iz skupine koju čine atom halogena, C1-C4 halogenalkil, nerazgranata ili razgranata C1-C6 alkilna, C3-C12 cikloalkilna, nerazgranata ili razgranata C1-C6 alkoksi i C3-C12 cikloalkoksi skupina; – R3 predstavlja šesteročlani heteroarilni prsten koji sadrži ugljik, vodik i jedan ili više atoma dušika, koji može biti supstituiran s jednim ili više supstituenata, koje se bira iz skupine koju čine atom halogena, C1-C4 halogenalkil, nerazgranata ili razgranata C1-C6 alkilna, C3-C12 cikloalkilna, nerazgranata ili razgranata C1-C6 alkoksi i C3-C12 cikloalkoksi skupina; N-oksid navedenih spojeva i njegova farmaceutski prihvatljiva sol, uz uvjet da spoj formule (I) nije: – 5-(piridin-4-il)-6-(piridin-4-il)piridin-2-amin, – 5-(piridin-3-il)-6-(piridin-3-il)piridin-2-amin, – 5-(pirazin-2-il)-6-(piridin-4-il)piridin-2-amin, – 5-(4-metilpiridin-2-il)-6-(piridin-4-il)piridin-2-amin.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što R3 predstavlja šesteročlani heteroarilni prsten koji sadrži jedan ili dva atoma dušika, koji može biti supstituiran s jednim ili više supstituenata, koje se bira iz skupine koju čine atom halogena, C1-C4 halogenalkil, nerazgranati ili razgranati C1-C6 alkil, C3-C12 cikloalkil, nerazgranati ili razgranati C1-C6 alkoksi i C3-C12 cikloalkoksi.
3. Spoj u skladu s patentnim zahtjevom 2, naznačen time što R3 predstavlja skupinu koju se bira između piridila ili pirimidinila, koji može biti supstituiran s jednim ili više supstituenata, koje se bira iz skupine koju čine atom halogena, C1-C4 halogenalkil, nerazgranati ili razgranati C1-C6 alkil, C3-C12 cikloalkil, nerazgranati ili razgranati C1-C6 alkoksi i C3-C12 cikloalkoksi.
4. Spoj u skladu s patentnim zahtjevom 3, naznačen time što se R3 bira između 3-piridilne ili 4-piridilne skupine, koja može biti supstituirana s jednim ili više supstituenata, koje se bira iz skupine koju čine atom halogena, C1-C4 halogenalkil, nerazgranati ili razgranati C1-C6 alkil, C3-C12 cikloalkil, nerazgranati ili razgranati C1-C6 alkoksi i C3-C12 cikloalkoksi.
5. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što R2 predstavlja piridilna skupina, koja može biti supstituirana s jednim ili više supstituenata, koje se bira iz skupine koju čine atom halogena, C1-C4 halogenalkil, nerazgranati ili razgranati C1-C6 alkil, C3-C12 cikloalkil, nerazgranati ili razgranati C1-C6 alkoksi i C3-C12 cikloalkoksi.
6. Spoj u skladu s patentnim zahtjevom 5, naznačen time što R2 predstavlja 4-piridilnu skupinu, koja može biti supstituirana s atomom halogena.
7. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što R1 predstavlja atom klora ili broma.
8. Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1 predstavlja atom klora ili broma, R2 predstavlja 4-piridilnu skupinu, koja može biti supstituirana s jednim ili dva atoma fluora, a R3 predstavlja skupinu koju se bira između 3-piridila ili 4-piridila, koji može biti supstituiran s jednim ili više supstituenata, koje se bira iz skupine koju čine atom halogena, C1-C4 halogenalkil, nerazgranati ili razgranati C1-C6 alkil, C3-C12 cikloalkil, nerazgranati ili razgranati C1-C6 alkoksi i C3-C12 cikloalkoksi.
9. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je jedan od: 5-(piridin-4-il)-6-(pirimidin-5-il)piridin-2-amina, 5-(3-fluorpiridin-4-il)-6-(pirimidin-5-il)piridin-2-amina, 6-(piridin-3-il)-5-(piridin-4-il)piridin-2-amina, 5-(3-fluorpiridin-4-il)-6-(piridin-3-il)piridin-2-amina, 6-(piridin-3-il)-5-(pirimidin-5-il)piridin-2-amina, 6-(5-fluorpiridin-3-il)-5-(3-fluorpiridin-4-il)piridin-2-amina, 5-(3-fluorpiridin-4-il)-6-(5-metoksipiridin-3-il)piridin-2-amina, 6-[5-(trifluormetil)piridin-3-il]-5-(3-fluorpiridin-4-il)piridin-2-amina, 6-(5-klorpiridin-3-il)-5-(3-fluorpiridin-4-il)piridin-2-amina, 5-(3-fluorpiridin-4-il)-6-(6-metoksipiridin-3-il)piridin-2-amina, 5-(3-fluorpiridin-4-il)-6-(piridin-4-il)piridin-2-amina, 5,6-bis-(3-fluorpiridin-4-il)piridin-2-amina, 5-(3-klorpiridin-4-il)-6-(piridin-3-il)piridin-2-amina, 5-(3-klorpiridin-4-il)-6-(piridin-4-il)piridin-2-amina, 5-(2-klor-6-metilpiridin-4-il)-6-(piridin-3-il)piridin-2-amina, 5-(2-metoksipiridin-4-il)-6-(piridin-3-il)piridin-2-amina, 3-klor-5-(piridin-4-il)-6-(pirimidin-5-il)piridin-2-amina, 3-brom-5-(piridin-4-il)-6-(pirimidin-5-il)piridin-2-amina, 3-klor-5-(3-fluorpiridin-4-il)-6-(pirimidin-5-il)piridin-2-amina, 3-brom-5-(3-fluorpiridin-4-il)-6-(pirimidin-5-il)piridin-2-amina, 3-klor-6-(piridin-3-il)-5-(piridin-4-il)piridin-2-amina, 3-brom-6-(piridin-3-il)-5-(piridin-4-il)piridin-2-amina, 3-klor-5-(3-fluorpiridin-4-il)-6-(piridin-3-il)piridin-2-amina, 3-brom-5-(3-fluorpiridin-4-il)-6-(piridin-3-il)piridin-2-amina, 3-klor-6-(piridin-3-il)-5-(pirimidin-5-il)piridin-2-amina, 3-brom-6-(piridin-3-il)-5-(pirimidin-5-il)piridin-2-amina, 3-klor-6-(5-fluorpiridin-3-il)-5-(3-fluorpiridin-4-il)piridin-2-amina, 3-brom-6-(5-fluorpiridin-3-il)-5-(3-fluorpiridin-4-il)piridin-2-amina, 3-klor-5-(3-fluorpiridin-4-il)-6-(5-metoksipiridin-3-il)piridin-2-amina, 3-brom-5-(3-fluorpiridin-4-il)-6-(5-metoksipiridin-3-il)piridin-2-amina, 3-klor-6-[5-(trifluormetil)piridin-3-il]-5-(3-fluorpiridin-4-il)piridin-2-amina, 3-brom-6-[5-(trifluormetil)piridin-3-il]-5-(3-fluorpiridin-4-il)piridin-2-amina, 3-klor-6-(5-klorpiridin-3-il)-5-(3-fluorpiridin-4-il)piridin-2-amina, 3-klor-5-(3-fluorpiridin-4-il)-6-(piridin-4-il)piridin-2-amina, 3-brom-5-(3-fluorpiridin-4-il)-6-(piridin-4-il)piridin-2-amina, 3-klor-5-(3-fluorpiridin-4-il)-6-(6-metoksipiridin-3-il)piridin-2-amina, 3-brom-5-(3-fluorpiridin-4-il)-6-(6-metoksipiridin-3-il)piridin-2-amina, 3-klor-5,6-bis-(3-fluorpiridin-4-il)piridin-2-amina, 3-klor-5-(3-klorpiridin-4-il)-6-(piridin-3-il)piridin-2-amina, 3-klor-5-(3-klorpiridin-4-il)-6-(piridin-4-il)piridin-2-amina, 3-klor-5-(2-klor-6-metilpiridin-4-il)-6-(piridin-3-il)piridin-2-amina, 3-klor-5-(2-metoksipiridin-4-il)-6-(piridin-3-il)piridin-2-amina.
10. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 9, kao i farmaceutski prihvatljivi razrjeđivač ili nosač.
11. Farmaceutski pripravak u skladu s patentnim zahtjevom 10, naznačen time što dodatno sadrži terapijski djelotvornu količinu terapijskog sredstva, kojeg se bira između pirfenidona, nintedaniba, antagonista LPA1 AM152, dopaminskih agonista, koje se bira između l-DOPA, ropinirola i pramipeksola, inhibitora enzima monooksigenaze B (MAO-B), koje se bira između selegilina i rasagilina, te inhibitora enzima acetilkolinesteraze, koje se bira između galantamina, rivastigmina, donepezila i takrina.
12. Kombinacijski proizvod, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 9 i terapijsko sredstvo, kojeg se upotrebljava u liječenju bolesti koje se bira iz skupine koju čine dišne bolesti, metabolički poremećaji, neurološke bolesti i rak.
13. Kombinacijski proizvod u skladu s patentnim zahtjevom 12, naznačen time što se terapijsko sredstvo bira između pirfenidona, nintedaniba, antagonista LPA1 AM152, dopaminskih agonista, koje se bira između l-DOPA, ropinirola i pramipeksola, inhibitora enzima monooksigenaze B (MAO-B), koje se bira između selegilina i rasagilina, te inhibitora enzima acetilkolinesteraze, koje se bira između galantamina, rivastigmina, donepezila i takrina.
14. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je namijenjen upotrebi kao medikament.
15. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je namijenjen upotrebi u liječenju bolesti ili patološkog stanja kojeg se bira iz skupine koju čine astma, kronična opstruktivna plućna bolest, idiopatska plućna fibroza, pretilost, dijabetes, ateroskleroza, staračka demencija, Alzheimerova bolest, Parkinsonova bolest i rak.
HRP20200044TT 2015-02-25 2020-01-10 Derivati 2-aminopiridina kao antagonisti adenozinskog receptora a2b i ligandi melatoninskih receptora mt3 HRP20200044T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201530233A ES2580702B1 (es) 2015-02-25 2015-02-25 Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
EP16705187.9A EP3262034B1 (en) 2015-02-25 2016-02-19 Derivatives of 2-aminopyridine as adenosine a2b receptor antagonists and ligands of the melatonin mt3 receptors
PCT/EP2016/053509 WO2016135048A1 (en) 2015-02-25 2016-02-19 Derivatives of 2-aminopyridine as adenosine a2b receptor antagonists and ligands of the melatonin mt3 receptors

Publications (1)

Publication Number Publication Date
HRP20200044T1 true HRP20200044T1 (hr) 2020-03-20

Family

ID=55398306

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200044TT HRP20200044T1 (hr) 2015-02-25 2020-01-10 Derivati 2-aminopiridina kao antagonisti adenozinskog receptora a2b i ligandi melatoninskih receptora mt3

Country Status (22)

Country Link
US (1) US10253017B2 (hr)
EP (1) EP3262034B1 (hr)
JP (1) JP6585729B2 (hr)
KR (1) KR102231924B1 (hr)
CN (1) CN107406425B (hr)
AU (1) AU2016223683B8 (hr)
BR (1) BR112017017704B1 (hr)
CA (1) CA2977905C (hr)
CY (1) CY1122497T1 (hr)
DK (1) DK3262034T3 (hr)
EA (1) EA032032B1 (hr)
ES (2) ES2580702B1 (hr)
HR (1) HRP20200044T1 (hr)
HU (1) HUE047751T2 (hr)
LT (1) LT3262034T (hr)
MX (1) MX2017010949A (hr)
PL (1) PL3262034T3 (hr)
PT (1) PT3262034T (hr)
RS (1) RS59862B1 (hr)
SI (1) SI3262034T1 (hr)
WO (1) WO2016135048A1 (hr)
ZA (1) ZA201706358B (hr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109651358B (zh) * 2017-10-11 2023-04-07 上海迪诺医药科技有限公司 4-氨基吡啶衍生物、其药物组合物、制备方法及应用
WO2020083957A1 (en) 2018-10-24 2020-04-30 Leadxpro Ag Functionalized aminotriazines
CN112592354B (zh) 2019-07-30 2022-05-27 厦门宝太生物科技股份有限公司 一种异噁唑并嘧啶类杂环化合物的制备方法
CN112479956A (zh) 2019-07-30 2021-03-12 杭州阿诺生物医药科技有限公司 一种用于制备腺苷受体抑制剂中间体的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001252606B2 (en) * 2000-04-26 2005-07-07 Eisai R&D Management Co., Ltd. Medicinal compositions promoting bowel movement
IL153995A0 (en) * 2000-08-11 2003-07-31 Eisai Co Ltd 2-aminopyridine derivatives and pharmaceutical compositions containing the same
FR2821843B1 (fr) 2001-03-12 2003-05-09 Servier Lab Nouveaux derives d'isoindoloindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2822153B1 (fr) 2001-03-19 2003-10-31 Servier Lab Nouveaux derives d'indenoindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2823153A1 (fr) 2001-04-05 2002-10-11 Jean Paul Begouen Amplification des pares soleils automobiles
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
FR2853649B1 (fr) 2003-04-09 2006-07-14 Servier Lab Nouveaux derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2003249604B2 (en) 2003-05-06 2011-06-30 Gilead Sciences, Inc. A2B adenosine receptor antagonists
FR2857011B1 (fr) 2003-07-04 2005-09-16 Servier Lab Nouveaux derives du benzothiophene 2-thiosubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0401336D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
ES2241496B1 (es) * 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
NZ589657A (en) 2004-10-15 2012-06-29 Gilead Palo Alto Inc Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
CA2612344A1 (en) 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
ES2270715B1 (es) * 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) * 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
CN104341386A (zh) * 2013-07-23 2015-02-11 中国科学院上海药物研究所 一类芳基杂环小分子化合物、其衍生物及其制备方法和用途

Also Published As

Publication number Publication date
DK3262034T3 (da) 2020-01-20
CN107406425B (zh) 2020-06-26
EP3262034B1 (en) 2019-12-04
KR102231924B1 (ko) 2021-03-25
PL3262034T3 (pl) 2020-07-13
MX2017010949A (es) 2017-12-15
EA032032B1 (ru) 2019-03-29
EP3262034A1 (en) 2018-01-03
KR20170140178A (ko) 2017-12-20
WO2016135048A1 (en) 2016-09-01
ZA201706358B (en) 2018-12-19
JP6585729B2 (ja) 2019-10-02
AU2016223683B2 (en) 2019-06-20
RS59862B1 (sr) 2020-03-31
AU2016223683A1 (en) 2017-10-05
BR112017017704B1 (pt) 2023-03-07
BR112017017704A2 (pt) 2018-04-10
ES2769999T3 (es) 2020-06-30
CN107406425A (zh) 2017-11-28
AU2016223683A8 (en) 2019-10-24
US10253017B2 (en) 2019-04-09
HUE047751T2 (hu) 2020-05-28
US20180037569A1 (en) 2018-02-08
AU2016223683B8 (en) 2019-10-24
ES2580702A1 (es) 2016-08-25
ES2580702B1 (es) 2017-06-08
LT3262034T (lt) 2020-01-10
EA201791881A1 (ru) 2018-01-31
JP2018506557A (ja) 2018-03-08
CA2977905C (en) 2021-01-19
SI3262034T1 (sl) 2020-03-31
CA2977905A1 (en) 2016-09-01
CY1122497T1 (el) 2020-10-14
PT3262034T (pt) 2020-02-10

Similar Documents

Publication Publication Date Title
HRP20200044T1 (hr) Derivati 2-aminopiridina kao antagonisti adenozinskog receptora a2b i ligandi melatoninskih receptora mt3
JP2018534326A5 (hr)
TWI732083B (zh) 苯并咪唑衍生物、其藥物組合物及其應用
US8486951B2 (en) Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
CN112771043B (zh) 取代吡唑稠环类衍生物及其制备方法和应用
AU2002363177B2 (en) Aminobenzamide derivatives as glycogen synthase kinase 3Beta inhibitors
JP2018503673A5 (hr)
TW200827358A (en) Compounds modulating C-FMS and/or C-KIT activity and uses therefor
JP2013527173A5 (hr)
AU2012299080B2 (en) Pyrimidine PDE10 inhibitors
SI3183247T1 (en) Aminopyrimidinyl compounds as inhibitors of JAK
JP2017501234A5 (hr)
CA2824415A1 (en) Benzamide derivatives as p2x7 receptor antagonists
TW201000457A (en) Novel heterocyclic compounds and uses therof
JP2015503571A5 (hr)
KR102396930B1 (ko) 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물
IL184717A (en) Imidazo (1,2-a)pyridine compounds as vegf-r2 inhibitors
JP2013544840A5 (hr)
TW200848050A (en) Sulfonyl amide derivatives for the treatment of abnormal cell growth
JP2017512786A5 (hr)
AU2020225048A1 (en) Novel pyrido(3,4-d)pyrimidin-8-one derivative having protein kinase inhibitory activity, and pharmaceutical composition for preventing, alleviating, or treating cancer, comprising same
JP2019534324A5 (hr)
RU2015100942A (ru) Производное пиперидинилпиразолпиридина
EP3066092A1 (en) Substituted pyridine derivatives useful as gsk-3 inhibitors
JP2018537408A5 (hr)